Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03787303 · ClinicalTrials.gov registry record · Phase 2
Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma
A Phase 2 study, sponsored by Aultman Health Foundation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03787303: Clinical Trial Phase 2 study, sponsored by Aultman Health Foundation.
NCT03787303 is a Phase 2 study that was terminated before completion, run by Aultman Health Foundation. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03787303, a Phase 2 study, was terminated before completion, sponsored by Aultman Health Foundation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Up to one third of breast cancer patients have hypothyroidism or hyperthyroidism. L-thyroxine (T4), or Synthroid, is the most commonly prescribed agent for the management of hypothyroidism in the US. However, there are data suggesting that triiodothyronine (T3) may have benefits in preventing disease progression over l-thyroxine (T4).
Primary Outcome
To prospectively evaluate the progression-free survival in hypothyroid patients with metastatic breast carcinoma who are rendered euthyroid and hypothyroxinemic. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the nadir sum of the longest diameter (SLD) of target lesions, or unequivocal progression (overall level of substantial worsening) in existing non-target lesions, or the appearance of one or more new lesions.
Interventions
- DRUG Triiodothyronine (T3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2022-03-09 |
| Phase | Phase 2 |
Why NCT03787303 stopped before completion
NCT03787303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Triiodothyronine (T3) is the first listed.
NCT03787303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03787303 about?
NCT03787303 is a clinical study titled "Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma". Up to one third of breast cancer patients have hypothyroidism or hyperthyroidism. L-thyroxine (T4), or Synthroid, is the most commonly prescribed agent for the management of hypothyroidism in the US. However, there are data suggesting that triiodothyronine (T3) may have benefits in preventing diseas...
What is the current status of trial NCT03787303?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-03-01. Estimated completion is 2022-03-09.
What interventions are being tested in trial NCT03787303?
The interventions under investigation include: Triiodothyronine (T3) (DRUG).
Who is sponsoring clinical trial NCT03787303?
This trial is sponsored by Aultman Health Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03787303's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI